Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26A1 | O43174 | 2/20 | 0.37 |
| ▸ | PGR | P06401 | 4/20 | 0.37 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.37 |
| ▸ | BDKRB1 | P46663 | 3/20 | 0.36 |
| ▸ | RARG | P13631 | 4/20 | 0.36 |
| ▸ | RARA | P10276 | 3/20 | 0.36 |
| ▸ | RARB | P10826 | 3/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | CTSC | P53634 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4518425 | 0.86 | CYP26A1 (0.37) | CYP26A1CYP26B1RARGRARARARB | |
| SCHEMBL5737841 | 0.76 | RARB (0.37) | CYP26A1CYP26B1RARGRARARARB | |
| SCHEMBL31147975 | 0.74 | ACLY (0.43) | BDKRB1RORC | |
| SCHEMBL5738690 | 0.74 | CYP26A1 (0.43) | CYP26A1CYP26B1RARGRARARARB | |
| SCHEMBL13613859 | 0.74 | CYP26A1 (0.34) | CYP26A1CYP26B1BDKRB1RARGRARA | |
| SCHEMBL7503018 | 0.71 | PGR (0.49) | PGRRARGRARBRXRA | |
| SCHEMBL15717088 | 0.68 | MALT1 (0.41) | PGR | |
| SCHEMBL13614264 | 0.68 | ALDH1A1 (0.40) | CYP26A1CYP26B1RARGRARARARB | |
| SCHEMBL8671302 | 0.68 | PGR (0.38) | PGRRARGRARARARBHSD17B1 | |
| SCHEMBL17276295 | 0.68 | RARG (0.42) | RARGRARARARBRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638648-B2 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-20080004455-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-7226951-B2 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. (US) | 2007-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004455-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | CYP1A2, CYP2A7, CYP3A7 | CYP26A1 15/4885PGR 517/4885CYP26B1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.